Trial Profile

A Multi-Center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 15 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AGS 16C3F (Primary) ; Axitinib
Indications Renal cell carcinoma
Focus Therapeutic Use
Sponsors Agensys; Astellas Pharma; Astellas Pharma Global Development

Most Recent Events

17 May 2021 Status changed from active, no longer recruiting to completed.
03 Mar 2020 Planned End Date changed from 1 Sep 2021 to 1 Sep 2020.
02 Aug 2019 Planned End Date changed from 1 Jun 2019 to 1 Sep 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com